Essilor: Disclosure of Share Capital and Voting Ri
Post# of 301275
Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2017
(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers )
Charenton-le-Pont, France (March 6, 2017 - 6.00 p.m.) - As of February 28, 2017, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:
| February 28, 2017 | |
| Shares outstanding | 218,530,045 |
| Exercisable voting rights | 233,082,728 |
| Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 235,128,468 |
(*) Shares held by the Company.
About Essilor The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ® , Crizal ® , Transitions ® , Eyezen TM , Xperio ® , Foster Grant ® , Bolon TM and Costa ® . It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit www.essilor.com . The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
------------------------
Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16
Attachments:
(0)
(0)